Dr. Lee is an expert in tumor infiltrating lymphocyte therapy, a form of immunotherapy that uses the patient’s own immune cells to attack their tumors. She leads Fred Hutch’s TIL program, one of only four in the U.S., which offers clinical trials of this approach to patients.
TILs are a type of T cell that attack cancer, but tumors are able to shut off this response before it can eradicate the disease. To harness TILs’ power, Dr. Lee and her colleagues extract these dormant cells from a piece of melanoma tumor and reactivate them in the lab. They then select those cells best able to recognize and attack the tumor and multiply those cells to the billions in the laboratory before reinfusing them into patients.
Dr. Lee leads a TIL trial for patients with melanoma. Early results suggest that tumors in the first patients treated are responding to the therapy.
Unlike some immunotherapies that target one cancer-specific protein, TIL therapy uses a mix of T cells, which may make it a better match for cancers that don’t harbor one universal target protein. Cancers driven by environmental toxins, such as melanoma and lung cancer, are prime candidates for TIL therapy due to their high rates of mutation.
Dr. Lee’s team is now performing preclinical work to develop TIL therapy for lung cancer, and they hope to expand the therapy to bladder cancer and head and neck cancer in the near future.
Dr. Sylvia Lee explains Fred Hutch's immunotherapy program and how it's giving hope to more patients.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.